GlassScriptPhysician profile
William M Dixon
NPI 1710964416
$4,084.55
in general payments reported to CMS, 2019-2025
43 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $566 · 2021: $788 · 2022: $496 · 2023: $490 · 2024: $665 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $658.13 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $405.21 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $273.07 | 2019-2024 | Airsupra |
| Abbott Laboratories | $269.04 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $199.86 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $173.88 | 2019-2024 | |
| Abbvie INC. | $149.25 | 2020-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.37 | 2019-2023 | Jardiance |
| Dexcom, INC. | $125.60 | 2020-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $111.78 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Abiomed | $111.11 | 2024 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.93 | 2020-2024 | Xifaxan, Trulance |
| Lundbeck LLC | $92.81 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $89.20 | 2019-2020 | |
| Daiichi Sankyo INC. | $85.48 | 2020-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $83.50 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $71.65 | 2019-2025 | Capvaxive, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $66.73 | 2022-2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $65.41 | 2019-2021 | |
| Exact Sciences Corporation | $65.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Stryker Corporation | $62.36 | 2025 | Clottriever Bold Catheter |
| Pfizer INC. | $57.70 | 2019-2024 | |
| Mylan Specialty L.P. | $56.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $52.69 | 2024-2025 | Rexulti |
| Medtronic, INC. | $51.04 | 2023 | Intellis Adaptivestim |
| Edwards Lifesciences Corporation | $50.52 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Organon LLC | $44.85 | 2021-2025 | Nexplanon |
| Genentech USA, INC. | $44.62 | 2021 | |
| Seqirus USA INC | $44.02 | 2024 | Fluad, Flucelvax |
| Globus Medical, INC. | $40.92 | 2025 | Senza |
| Sanofi Pasteur INC. | $30.59 | 2020-2025 | |
| Kerecis Limited | $28.58 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Allergan, INC. | $25.46 | 2020 | |
| Redhill Biopharma INC. | $25.39 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $20.70 | 2023 | |
| Corcept Therapeutics | $19.66 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $19.01 | 2024 | Onpattro |
| Inspire Medical Systems, INC. | $14.36 | 2023 | Inspire |
| Biotronik INC. | $14.17 | 2021 | |
| Cvrx, INC. | $12.93 | 2025 | Barostim Neo System |
| Evofem Biosciences, INC. | $12.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.47 | 2020 | |
| Insmed, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.